Atsena Reports Early XLRS Gene-Therapy Signal
Atsena reported preliminary Phase I/II/III LIGHTHOUSE data for ATSN-201 in X-linked retinoschisis, including functional and anatomical responses at the selected pivotal dose and no drug-related serious adverse events or dose-limiting toxicities. The results are…
